Navigation Links
Data From Anthera's Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions
Date:2/7/2008

SAN MATEO, Calif., Feb. 7 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that data from the Phase II trial of its novel secretory phospholipaseA2 inhibitor Varespladib (A-002) for the treatment of coronary heart disease will be presented as a late breaker at the 2008 American College of Cardiology 57th Annual Scientific Session on Monday, March 31, 2008 in Chicago, Illinois.

The Phase II trial known as PLASMA (Phospholipase Levels And Serological Markers of Atherosclerosis) was a multi-center, randomized, double-blind, placebo-controlled trial that enrolled approximately 400 patients with stable coronary heart disease in the U.S. and Ukraine. Subjects were randomized to receive one of four different doses of A-002 or placebo for up to eight weeks. Patients also received doctor-determined standard of care therapies. The primary endpoint was a reduction in secretory phospholipase A2 (sPLA2). The study also evaluated the effect of Varespladib on cholesterol levels (LDL-C, non-HDL and total cholesterol) as well as inflammation in patients with stable coronary heart disease.

PLASMA Late-Breaker Trial Data Presentation:

Date/Time: Monday, March 31 from 2:30-2:45pm.

Title/Author: Effects of a Selective Inhibitor of Secretory

Phospholipase A2 on Low Density Lipoproteins and Inflammatory Pathways,

Robert S. Rosenson, MD, Director, Lipoprotein Disorders and Clinical

Atherosclerosis Research, Division of Cardiovascular Medicine at the

University of Michigan, for the PLASMA Investigators.

Location: McCormick Place, Vista Room S406

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and a
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation
2. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
3. Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study
4. Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program
5. Toxoplasma infection increases risk of schizophrenia, study suggests
6. New Heart Pump Shows Promise in Trial
7. Trial to Test Gene Therapy for Angina in Women
8. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
9. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. MDS Pharma Services Wins Award for Management of Global Malaria Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... This report provides quantitative analysis ... The analysis includes market size data by revenue ... company share data by revenue in 2013 for ... It uses data and information sourced from proprietary ... , Scope,     Information on market ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 BCC ... report, SYNTHETIC BIOLOGY: GLOBAL MARKETS , the ... to nearly $11.9 billion in 2018, with a ... Enabled products account for the fastest growing segment, ... CAGR. Synthetic biology-enabled products in the pharmaceutical/diagnostics, chemical, ...
(Date:7/14/2014)... July 14, 2014 Secure Decisions, a ... is partnering with the Software Assurance Marketplace (SWAMP) to ... the software that drives everyday life. , The SWAMP, ... housed in the Morgridge Institute for Research, is funded ... advance software security practices by building a free facility ...
(Date:7/14/2014)... Clearwater, Florida (PRWEB) July 14, 2014 ... Summer Open House event will be held at the ... Wednesday July 16th from 4-8pm. Wine and other refreshments ... advantage of retail discounts on beauty products ... skin treatment known as dermaplaning. , Dermaplaning (also ...
(Date:7/14/2014)... July 14, 2014 The Encino ... now offering Lumineers and porcelain veneers. These ... that require more preparation and greater loss of healthy ... shells to conceal visible flaws on the tooth. Encino ... closely with patients to ensure they offer the most ...
Breaking Medicine News(10 mins):Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 3Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 4Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2
... finds cavities before X-rays allowing, dentists to ... TORONTO, July 3 /PRNewswire/ - Quantum Dental ... technology which,detects and monitors the early onset of ... reduces the number of invasive and painful procedures,and ...
... G8 failure on food prices, biofuels, and climate ... world,s population - at risk of hunger, warns,anti-poverty ... ahead of the G8,summit in Hokkaido, Japan, ActionAid ... has Contributed to the Global Food Crisis and ...
... completely fabricated,item about GO3 Omega-3 fish oil capsules ... Star magazine, none of the parties named in ... magazine prior to publication., (Photo: http://www.newscom.com/cgi-bin/prnh/20080702/LAW528 ... and will vigorously pursue any,organization making false claims ...
... Roger Mason Jr,Washington Wizards Guard and Washington, ... a Cause on July 29 featuring bowling at ... coming out to support the,cause, including Brendan Haywood ... Anthony, Allen Iverson, Vince Carter, Kevin Durant, and,Chris ...
... Technology could one day help tailor treatments to individual patients, ... new technique for finding and analyzing stray cancer cells in ... for doctors to one day not only determine the genetic ... cells and adjust treatments accordingly. , "I think this ...
... John Albright, MD, will join three other physicians as a 2008 ... , ... Orlando, Florida (PRWEB) July 2, 2008 -- ... three other physicians as a 2008 American Orthopaedic Society for ...
Cached Medicine News:Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 2Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 3Health News:ActionAid Challenges G8 on Response to Food Crisis 2Health News:GO3 Statement Regarding Erroneous Coverage in Star Magazine 2Health News:Washington Wizards Guard Roger Mason Jr. to Host Bowling at Lucky Strike to Benefit National Kidney Foundation of the National Capital Area 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 3Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 3
(Date:7/14/2014)... , July 14, 2014 Lumin Medical ... the assets of PatientTrak, the leading provider of on-demand ... from Illinois to ... is Lumin which means light and our mission is ... patient satisfaction, increase efficiencies and reduce costs," said ...
(Date:7/14/2014)... N.J. , July 14, 2014  Invivotek ... LLC is pleased to announce that its animal ... Association for the Assessment and Accreditation of Laboratory ... treatment of animals in science worldwide through voluntary ... standards for animal care and use in 38 ...
(Date:7/14/2014)... 14, 2014  Remedy Informatics, the leading provider ... and life sciences research, announced that it has ... to build the first-ever national patient registry devoted ... pancreatitis. "The National Pancreas Foundation is ... thoughtful and committed organizations can effect upon society ...
Breaking Medicine Technology:Lumin Medical Purchases PatientTrak 2Lumin Medical Purchases PatientTrak 3Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 3
... 4, 2012  Elevation Pharmaceuticals, Inc. announced today the closing ... investor Novo Ventures , to fund development of Elevation,s ... disease (COPD). All previous investors participated in the round, including ... Capital and Mesa Verde Venture Partners . In ...
... 4, 2012 /PRNewswire-iReach/ -- DFH Pharma, ... focused exclusively in the HIV-1 therapeutic space, announced ... medicinal chemistry services to support DFH efforts to ... drugs. Maturation inhibitors are a novel class of ...
Cached Medicine Technology:Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy 2Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy 3DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 3
Round knurled handle. Overall length 130 mm....
Optimum Extra Strength cleaner is a sterile non-preserved cleaning solution for use with fluorosilicone acrylate and silicone acrylate rigid gas permeable (RGP) and all hard contact lenses of any pol...
Round knurled handle. Overall length 130 mm....
Hosford foreign body spud 4 3/4 inches, gouge blade 1 x 7 mm rounded tip, angled to left....
Medicine Products: